Welcome to the e-CCO Library!

P623: Quality of life as predictor of biological levels decay in inflammatory bowel diseases
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Ceballos1*, M.D. Fiuza2, I. Alarcón3

Created: Thursday, 21 February 2019, 9:14 AM
P623: The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study
Year: 2022
Source: ECCO'22
Authors: Mahajna, H.(1);Abu-Salah, R.(1);Tzur, M.(1);Kedar, N.(1);Ben-Horin, S.(1);Kopylov, U.(1);Engel, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P623: The impact of SARS-CoV-2 outbreak on the treatment adherence and clinical outcome of patients with inflammatory bowel disease treated with biological agents.
Year: 2021
Source: ECCO'21 Virtual
Authors: Martino, G.(1);Carparelli, S.(1);Marseglia, A.(2);Pastore, M.R.(2);Placentino, M.(3);Nardella, M.(1);Guerra, M.(1);Palmieri, O.(1);Latiano, A.(1);Perri, F.(1);Ercolino, F.(1);Bossa, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P623: Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gonczi L.*1, Vegh Z.1, Kurti Z.1, Lovasz B.D.1, Golovics P.A.1, Fadgyas-Freyler P.2, Gimesi-Orszagh J.2, Gecse K.B.1, Lakatos P.L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P624 Maintenance of remission after treatment with Exclusive Enteral Nutrition and Azathioprine in paediatric patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Pujol Muncunill, A.I. Pascual-Pérez, P. Dominguez-Sánchez, S. Feo-Ortega, M. Suárez-Galvis, V. Vila-Miravet, F.J. Martin de Carpi

Created: Thursday, 30 January 2020, 10:12 AM
P624: A higher prevalence of human papillomavirus in patients with perianal fistulizing Crohn's disease compared to patients with anorectal fistula without Crohn's disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Rodrigues Boarini, L.(1);Sobrado Jr, C.W.(1);Facanali, C.B.G.(1);Queiroz, N.S.F.(1);Albuquerque, I.C.(2);Boarini, P.(3);Boarini, M.R.(4);Borba, M.R.(1);Nahas, S.C.(1);Cecconello, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P624: Chromoendoscopy and narrow band imaging versus conventional white light endoscopy for detection of neoplasia in ulcerative colitis – a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Har-Noy O.1, Katz L.1, Avni T.2, Bessissow T.3, Young D.4, Koulaouzidis A.4, Engel T.1, Eliakim R.1, Ben-Horin S.1, Kopylov U.*5

Created: Wednesday, 20 February 2019, 10:36 AM
P624: Factors that may influence the development of anti-drug antibodies to adalimumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, I. Rauter2, L. Chen3, M. Gessner3, G. Fanjiang3

Created: Friday, 22 February 2019, 9:41 AM
P624: Investigating the symptom burden among European patients with moderate-to-severe Crohn's disease using a real-world survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: BurischPhD, J.(1)*;Hart, A.(2);Sturm, A.(3);Knight, H.(4);Rudolph, C.(5);Meadows, R.(4);Oortwijn, A.(5);Weatherby, S.(4);Rolph, R.(6);Dawod, F.(4);Armuzzi, A.(7);
Created: Friday, 14 July 2023, 11:05 AM
P624: Long-term effectiveness of anti-TNF therapy in pediatric-onset inflammatory bowel diseases: a population-based study
Year: 2022
Source: ECCO'22
Authors: Fumery, M.(1);Savoye, G.(2);Ley, D.(3);Dupont, C.(4);Bertrand, V.(5);Spyckerelle, C.(6);Guillon, N.(3);Desreumaux, P.(7);Gower-Rousseau, C.(8);Sarter, H.(9);Turck, D.(3);Leroyer, A.(9);
Created: Friday, 11 February 2022, 3:56 PM
P624: Vedolizumab can induce clinical remission in patients with chronic antibiotic-refractory pouchitis: A retrospective single-centre experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, C. Claeys1, G. Van Assche1,2, A. D'Hoore3, A. Wolthuis3, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
P625 Kinetics and outcomes of transmural healing in patients with Crohn’s disease treated with anti-TNF therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Pastaud1, C. Hordonneau2, C. Lambert3, J. Vignette1, B. Pereira3, A. Buisson1

Created: Thursday, 30 January 2020, 10:12 AM
P625: A prospective study to assess the effectiveness of tacrolimus therapy in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Kishi*, F. Hirai, N. Takatsu, Y. Takada, Y. Yutaka, T. Takeda, K. Yao, T. Matsui, T. Ueki

Created: Thursday, 21 February 2019, 9:14 AM
P625: Characteristics of SARS-CoV-2 infection in IBD patients in the second and third wave compared with the first wave and with the data of general population
Year: 2021
Source: ECCO'21 Virtual
Authors: Guerra Marina, I.(1);Algaba, A.(1);Castro, S.(2);Jiménez, L.(1);Garza, D.(1);Aller, M.D.M.(1);Granja, A.(1);Guardiola, A.(1);Gil, M.(2);Ruiz, P.(2);Bermejo, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P625: Head-to-head comparison of three stool calprotectin tests for home use
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S-M. Haisma*1, A. Galaurchi2, S. Almahwzi2, J. Adekanmi Balogun2, A. Muller Kobold3, P. van Rheenen1

Created: Friday, 22 February 2019, 9:41 AM
P625: Predictors of pancreatitis among patients with inflammatory bowel disease (IBD) treated with vedolizumab (VDZ): Observation from a large global safety database
Year: 2022
Source: ECCO'22
Authors: Wernicke, J.(1);Verstak, T.(1);Zhang, T.(1);Spalding, W.(1);Lee, L.(1);Cheng, Y.(1);Ademi, A.(1);
Created: Friday, 11 February 2022, 3:56 PM
P625: Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Llaó, J.(1);Martín-Arranz, E.(2);Zabana, Y.(3);Navarro-Llavat, M.(4);Garcia-Planella, E.(5);Busquets, D.(6);Monfort, D.(7);Pineda, J.R.(8);Gutiérrez, A.(9);Villoria, A.(10);Menchén, L.(11);Bastida, G.(12);García-Alonso, F.J.(13);Rivero, M.(14);Chaparro, M.(15);Riestra, S.(16);Merino, O.(17);Rodríguez-Lago, I.(18);Barreiro-de-Acosta, M.(19);Domènech MoralPhD, E.(20)*;
Created: Friday, 14 July 2023, 11:05 AM
P625: Ustekinumab use in Crohn's disease: effectiveness of dose escalation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Greenup A., Rosenfeld G., Bressler B.

Created: Wednesday, 20 February 2019, 10:36 AM
P626 Patients with IBD seek extra supportive care: insights from Israeli social media networks
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. SHARVIT1, I. Goren1,2, L. Godny1,2, K. Yadgar2, S. Elial Fatal2, R. Barkan2, D. Turner3, I. Dotan1,2, H. Yanai1,2

Created: Thursday, 30 January 2020, 10:12 AM
P626: Anti-TNF monotherapy is associated with an adverse clinical outcome in female Inflammatory Bowel Disease patients who stop Anti-TNF treatment during the third trimester of pregnancy.
Year: 2022
Source: ECCO'22
Authors: Lastiri, E.(1);Herrera-De Guise, C.(1);Casellas, F.(1);Mayorga, L.(1);Robles, V.(1);Cespedes, E.(1);Perez, Z.(1);Oller, E.(1);Borruel-Sainz, N.(1);
Created: Friday, 11 February 2022, 3:56 PM